ArticleCell stem cell2012
In epigenetic therapy, less is more.
Article in Cell stem cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma.Translational oncology · 2025Review
- The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.Journal of experimental & clinical cancer research : CR · 2025Article
- Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles.Frontiers in neurology · 2023Article
- Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs.Pharmacology & therapeutics · 2022Review
- Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Frontiers in oncology · 2022Review
- Loci specific epigenetic drug sensitivity.Nucleic acids research · 2020Article
- Epigenetic mechanisms as a new approach in cancer treatment: An updated review.Genes & diseases · 2018Review
- Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.Theranostics · 2018Article
- Combining Epigenetic and Immunotherapy to Combat Cancer.Cancer research · 2016Review
- DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.Cell reports · 2016Article
- DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys.The Journal of clinical investigation · 2016Article
- Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines.Clinical proteomics · 2016Article
- Episensitization: Defying Time's Arrow.Frontiers in oncology · 2015Review
- DNA Methylation and Colorectal Cancer.Current colorectal cancer reports · 2014Article
- A reciprocal role of prostate cancer on stromal DNA damage.Oncogene · 2014Article
- DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia.Epigenetics · 2014Article
- Harnessing the potential of epigenetic therapy to target solid tumors.The Journal of clinical investigation · 2014Review
- Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia.Genome biology · 2013Article
- Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.Cancer research · 2013Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
How DNA methylation inhibitors exert their anticancer effects in patients is not well understood. In the latest issue of Cancer Cell, Tsai et al. (2012) use low-dose drug treatment to induce persistent attenuation of tumorigenicity by targeting tumor-initiating cells.
Identifiers
22482500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.